Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study

Abstract

Iloprost is effective for the short-term palliation of severe Raynaud phenomenon in patients with systemic sclerosis.